Skip to content
value.today

Mesoblast Limited

MSB.AX
$169 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$17 M
For year ending June-2025
Net income
$-102 M
-593.8% margin
SEC filing
Employees
—

Mesoblast Limited in brief

Mesoblast Limited is a listed company in the Biotechnology industry, based in Australia. Its last known market value was $169 M (January 2024); there is no current figure. In the year to June 2025 it had sales of $17 M and a net loss of $102 M. Its largest product and service lines by sales in 2026 were Ryoncil (96%). Its shares trade under the symbol MSB.AX (ASX).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Mesoblast Limited

Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Mesoblast Limited timeline

1 events, 2004
  1. 2004
  2. 📈
    Listed on Australian Securities Exchange as MSB

Events of Mesoblast Limited from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$274 M$549 M$823 M$1.1 B20202021202220232024

World rank over time

▼ down 9,968 places since 2020
2020-01-01: #8800#8,80020202021-01-01: #7886#7,88620212022-01-07: #12197#12,19720222022-12-25: #13219#13,21920222023-07-30: #11378#11,37820232024-01-05: #18768#18,7682024

Rank in Australia: #180 (Jan 2020) · #176 (Jan 2021) · #277 (Jan 2022) · #264 (Dec 2022) · #229 (Jul 2023) · #399 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-593.8%
Operating margin
—
Return on equity
-17.1%
Liabilities / assets
23.9%
Net debt
$-94M
Revenue growth
+191.5%
R&D / revenue
202.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2018: revenue $17M, net income $-35M$17MFY18Fiscal year ending Jun 2019: revenue $17M, net income $-90M$17MFY19Fiscal year ending Jun 2020: revenue $32M, net income $-78M$32MFY20Fiscal year ending Jun 2021: revenue $7M, net income $-99M$7MFY21Fiscal year ending Jun 2022: revenue $10M, net income $-91M$10MFY22Fiscal year ending Jun 2023: revenue $8M, net income $-82M$8MFY23Fiscal year ending Jun 2024: revenue $6M, net income $-88M$6MFY24Fiscal year ending Jun 2025: revenue $17M, net income $-102M$17MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2025$17M+191.5%—$-102M-593.8%
Jun 2024$6M-21.3%—$-88M-1490.8%
Jun 2023$8M-26.5%—$-82M-1091.9%
Jun 2022$10M+37.4%—$-91M-894.7%
Jun 2021$7M-76.9%—$-99M-1329.9%
Jun 2020$32M+92.3%—$-78M-242.4%
Jun 2019$17M-3.6%—$-90M-537.1%
Jun 2018$17M——$-35M-203.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2025$-50M$1M$-51M$-0.08—
Jun 2024$-48M$0M$-49M$-0.09—
Jun 2023$-63M$0M$-64M$-0.11—
Jun 2022$-66M——$-0.13—
Jun 2021$-101M——$-0.16—
Jun 2020$-50M——$-0.15—
Jun 2019$-58M——$-0.18—
Jun 2018$-75M——$-0.08—

SEC filings

Official filings of Mesoblast Limited with the US Securities and Exchange Commission.

Annual results

Revenue
$17 M
Operating income
—
Net income
$-102 M

For year ending June-2025 · source: SEC filing

Balance sheet

Total assets
$785 M
Total liabilities
$187 M
Total equity
$597 M

As of June-2025

Mutual funds holding Mesoblast Limited#

39 funds in 2 countries hold shares worth $74 M. Since their previous reports 11 added shares and 16 sold, selling $5 M net. By country: USA 38 ($73 M), Sweden 1 ($1 M).
Mutual funds holding Mesoblast Limited
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc.12.01 M$17 M—<0.01%−12%Jul 31, 2026
🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc.8.01 M$11 M—<0.01%−11%Jun 30, 2026
🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors6.88 M$10 M—<0.01%+1.2%Jul 31, 2026
🇺🇸 The Asia Pacific Small Company SeriesDimensional Fund Advisors LP4.45 M$6 M—0.37%−5.0%Jul 31, 2026
🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc.3.11 M$4 M—0.03%−11%Jul 31, 2026
🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors3.07 M$4 M—0.03%−15%Jul 31, 2026
🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc.1.99 M$3 M—0.05%+2.3%May 31, 2026
🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP1.26 M$2 M—0.03%−8.6%Jul 31, 2026
🇺🇸 iShares Core MSCI International Developed Markets ETFBlackRock Fund Advisors1.23 M$2 M—<0.01%+4.7%Jul 31, 2026
🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc.1.18 M$2 M—<0.01%−0.1%Jun 30, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP1.05 M$2 M—<0.01%+2.9%Jul 31, 2026
🇺🇸 Vanguard Pacific Stock Index FundThe Vanguard Group, Inc.878,924$1 M—<0.01%−13%Jul 31, 2026
🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP775,076$1 M—<0.01%+0.8%Jul 31, 2026
🇺🇸 iShares Core MSCI Total International Stock ETFBlackRock Fund Advisors749,779$1 M—<0.01%newJul 31, 2026
🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc.701,866$1 M—<0.01%no changeJul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC598,611$1 M—<0.01%−14%Jun 30, 2026
🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC489,428$1 M—<0.01%no changeJul 31, 2026
🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB503,943$1 M—0.02%+27%Jun 30, 2026
🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP399,292$1 M—<0.01%−3.9%Jul 31, 2026
🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP378,277$1 M—<0.01%no changeJul 31, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP379,344$1 M—0.01%no changeJul 31, 2026
🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc.279,136$0 M—<0.01%no changeJun 30, 2026
🇺🇸 iShares Core MSCI Pacific ETFBlackRock Fund Advisors245,596$0 M—0.01%+3.3%Jul 31, 2026
🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC236,720$0 M—0.03%−8.6%Jul 31, 2026
🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc.200,912$0 M—<0.01%+20%May 31, 2026
🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP173,604$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Innovate Equity ETFGoldman Sachs Asset Management, L.P.101,936$0 M—0.07%−3.5%May 31, 2026
🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust100,665$0 M—0.05%+19%May 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP106,728$0 M—0.04%no changeJul 31, 2026
🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP103,674$0 M—<0.01%−22%Jul 31, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP98,564$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC79,233$0 M—0.02%no changeJun 30, 2026
🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors48,709$0 M—0.01%−28%May 31, 2026
🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC37,977$0 M—0.04%no changeJun 30, 2026
🇺🇸 Dimensional International Sustainability Core 1 ETFDimensional Fund Advisors LP35,588$0 M—<0.01%no changeJul 31, 2026
🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation37,595$0 M—<0.01%no changeJun 30, 2026
🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc.29,959$0 M—<0.01%+14%Jun 30, 2026
🇺🇸 FlexShares Morningstar Developed Markets ex-US Factor Tilt Index FundNorthern Trust Investments, Inc.22,320$0 M—<0.01%no changeJul 31, 2026
🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC8,774$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Mesoblast Limited#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
37.5 M
30 purchases, 1 insider
Sold, 12 months
0
0 sales, 0 insiders
Net, 12 months
37.5 M
open market only
Insiders on file
1
since
Mesoblast Limited: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gregory GeorgeDirector, 10% ownerBuyindirect+2.32 M1.4803.4 Mlocal8.32 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+2.32 M1.4803.4 Mlocal8.32 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+886,8901.4301.3 Mlocal12.89 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+105,0001.460153 Klocal12.99 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+500,0001.440720 Klocal13.49 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+10,0001.44014 Klocal13.50 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+4,7601.4407 Klocal13.51 MForm 4
filed Gregory GeorgeDirector, 10% ownerBuyindirect+20,0001.43029 Klocal13.53 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: Mesoblast Limited#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.6 M
10.16 days to cover

Fails to deliver

  • : 4,216 shares at $15.67
  • : 213 shares at $13.39
  • : 119 shares at $13.18
  • : 1,108 shares at $12.39
  • : 1,793 shares at $12.28

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Mesoblast Limited scorecard#

Passes 6 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in profitability (0 of 3). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth3 of 6
    • ✓Revenue grew in the newest year191.5%Revenue up 191.5% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years19.0%19.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median19.0%19.0% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.08 vs -0.09Diluted EPS -0.08 in fiscal 2025 against -0.09 the year before (report's currency).
    • ✗Net income higher than five years earlier-$102 M-$102 M in fiscal 2025 against -$78 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$102 MNet income -$102 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-18.9%-18.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 4
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.99 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $94 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year22.4%Diluted shares up 22.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Mesoblast Limited's statements, beside the median of Biotechnology.

Mesoblast Limited: main financial ratios in 2025
Ratio2025Median of peers
Net margin-593.8%-68.9%
Return on equity-19.0%-61.0%
Revenue growth, 3 years a year19.0%12.9%
Revenue growth191.5%15.8%
Debt to equity0.11×0.26×
Free cash flow margin-294.4%-61.5%

5of 9on the Piotroski tests of financial strength

  • Net loss of $102 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$51 million.
  • The share count rose 22.4% in the year.
  • More cash than debt: net cash of $94 million.

Mesoblast Limited: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Mesoblast Limited: statements by fiscal year
PeriodTrendFY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017FY 2016to Jun 30, 2016
Income statement
Revenue175.97.510r7.4r3217172.443
Cost of revenue5.100———————
Research and development3540r53r33535660665950
Selling, general and administrative392527———————
Interest and finance income3.61.80.80.00.00.50.70.40.51.1
Interest expense and finance costs232320171114r12r1.8——
Income before tax−102−88−82−92−100−87−99−66−90−91
Income tax0.3−0.2−0.2−0.2−0.8−9.4−9.0−31−13−87
Net income including minority interests−102−88−82−91−99−78−90−35−77−4.1
Net income attributable to shareholders−102−88−82−91−99−78−90−35−77−4.1
Earnings per share, basic-0.08-0.09-0.11r-0.13r-0.16-0.15-0.18-0.08-0.19-0.01
Earnings per share, diluted-0.08-0.09-0.11r-0.13r-0.16-0.15-0.18-0.08-0.19-0.01
Shares, weighted average (basic)1,208987778r683r605529494466399364
Shares, weighted average (diluted)1,208987778r683r605529494466399364
Balance sheet
Cash and cash equivalents16263716013712950384681
Receivables15217.04.44.81.64.1503.7—
Inventory220————————
Current assets2048682701481376310164—
Property, plant and equipment1.71.11.42.03.02.30.81.11.83.1
Right-of-use (leased) assets4.12.75.17.99.18.0————
Non-current assets580583588592596597590591592—
Total assets785669669662745734652692656—
Accounts payable197.120232025131922—
Current liabilities1037342519490442437—
Long-term debt681001039241576759——
Lease liabilities (non-current)3.62.03.77.18.56.3————
Non-current liabilities851161261146994127122102—
Total liabilities187189168165163184171146139—
Retained earnings−1,011−909−821−739−648−549−470−380−345—
Total equity597480502497581549481546517528
Cash-flow statement
Depreciation and amortization6.44.74.14.44.33.72.12.73.12.2
Share-based compensation225.93.75.5137.54.46.25.33.4
Cash from operating activities−50−48−63−66−101r−50r−58−75−95−88
Capital expenditure−0.7−0.3−0.3———————
Intangible assets bought−0.1−0.1−0.1−0.10−0.2————
Cash from investing activities0.1−0.1−0.2−0.2−1.6−3.3−1.0−1.20.1−1.7
Debt issued—005200.54432——
Debt repaid−7.8−100−550−0.5————
Shares issued16165890.210614530416269
Cash from financing activities1474075−9.9109r131r72696062
Exchange-rate effect on cash1.1−0.1−0.2−0.61.41.5−0.2−0.40.1−2.1
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Mesoblast Limited sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Ryoncil$115 M96%

Source: SEC annual report (XBRL data) · as of Jun 30, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Mesoblast Limited
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$7 MPrivate placement after listing$2 to $10 million2equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Mesoblast Limited compares in Biotechnology

  • Revenue$17 M · higher than 49% of 647
  • Net margin-593.8% · higher than 10% of 408
  • Revenue growth191.5% · higher than 89% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Mesoblast Limited🇦🇺$169 M—-593.8%+191.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending June-2025
Balance sheet:
As of June-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, Wikipedia, Wikidata; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Mesoblast Limited? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Mesoblast Limited's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Mesoblast Limited? Suggest a correction